Donoghoe Nicholas 4
4 · AbbVie Inc. · Filed Feb 18, 2025
Insider Transaction Report
Form 4
AbbVie Inc.ABBV
Donoghoe Nicholas
EVP, CHIEF BUS/STRAT OFFICER
Transactions
- Award
Common Stock, $0.01 par value
2025-02-13+11,017→ 66,920 total - Award
Common Stock, $0.01 par value
2025-02-13+4,520→ 71,440 total - Award
Common Stock, $0.01 par value
2025-02-13+4,634→ 76,074 total - Award
Common Stock, $0.01 par value
2025-02-13+5,174→ 81,248 total - Award
Option (Right to buy)
2025-02-13+23,437→ 23,437 totalExercise: $192.86Exp: 2035-02-12→ Common Stock (23,437 underlying)
Footnotes (5)
- [F1]Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025.
- [F2]Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025.
- [F3]Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025.
- [F4]Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025.
- [F5]Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 7,813 on February 13, 2026, 7,812 on February 13, 2027, and 7,812 on February 13, 2028.